（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，国大药房目前强调稳健和提 质增效，短期不太会有并购计划，会把重点放在现有店铺经营能力的提升方面。未来行业进入稳定阶 段，不排除再进行扩张的可能。 ...

Core Viewpoint - The company announced that it conducts annual impairment tests on goodwill in accordance with accounting standards and policies, with results pending further evaluation after the second half of the year [1] Group 1 - The company stated that it reflects the value of goodwill assets accurately based on the results of impairment tests [1] - Current conditions regarding goodwill are relatively stable, with specific results to be assessed later [1]

（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，公司去年年初制定了三年的 分红承诺，即不低于20%派息率，但今年已经做到超过30%。从长远来看，公司会结合现金的实际情况 进行分红，也会在经营条件允许的范围内给投资者合理回报，总体不会低于20%。 ...

（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，公司对分销的整体预期是与 去年基本持平。集采扩面、支付改革对利润率的压力客观存在，但集采商品的回款周期将会缩短。此 外，公司有效填补缺口的模式是国产和进口新药的上市速度变快，医保也给予适当通路。同时，公司也 在持续推动医院的SPD项目的推广，目前成效较好。 ...

Core Viewpoint - The company reported a significant decline in operating cash flow for the first half of the year, primarily due to extended payment terms in its distribution business and negative sales growth in Guoda Pharmacy [1] Group 1 - The operating cash flow decreased year-on-year, indicating potential liquidity issues for the company [1] - Extended payment terms in the distribution business have negatively impacted cash flow [1] - Guoda Pharmacy experienced a decline in sales revenue, contributing to reduced positive cash flow [1]

证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，广西市场，根据已经披露的 半年报来看，广西公司与主要竞争对手差距越来越小，公司在广西市场的市占率有所提升。广东市场， 主要对手的整体规模仍保持正增长，但本公司净利润率远高于对方，而且我们在公立医院市场的份额仍 保持增长，保持良好的竞争态势。等市场环境好转后，公司会继续扩大相应的市场份额。 （编辑 袁冠琳） ...

证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，从行业平均水平来看，净利 润率大概处在中低个位数。过往国大药房的净利润偏低，主要还是与其产品结构有关，公司将会通过产 品品类优化进一步改善毛利率，通过费用节约，进而改善净利率，公司认为还有一定空间。 （编辑 袁冠琳） ...

Group 1 - The core viewpoint of the article highlights that the O2O (Online to Offline) business model is expanding opportunities for physical pharmacies, but the platform service fees are impacting their profitability [1] - The company, Guoda Pharmacy, is actively communicating and coordinating with various platform enterprises to seek cost savings amid competition [1] - O2O is recognized as a trend in the industry, prompting physical pharmacies to maintain their uniqueness to cope with pricing pressures from online products [1]

Core Points - The pharmaceutical commercial sector experienced a decline of 0.96% on September 3, with First Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.14, up 2.27% with a trading volume of 106,600 shares and a transaction value of 279 million [1] - Yifeng Pharmacy (6666609) closed at 24.93, up 2.09% with a trading volume of 203,900 shares and a transaction value of 507 million [1] - Zhejiang Nongyuan (000705) closed at 9.28, up 0.65% with a trading volume of 207,300 shares and a transaction value of 195 million [1] - Guoyao Co. (600511) closed at 29.34, down 0.44% with a trading volume of 40,900 shares and a transaction value of 120 million [1] - Shanghai Pharmaceutical (601607) closed at 18.48, down 0.65% with a trading volume of 202,100 shares and a transaction value of 373 million [1] - Jiuzhoutong (600998) closed at 5.01, down 0.99% with a trading volume of 437,600 shares and a transaction value of 220 million [1] - Nanjing Pharmaceutical (600713) closed at 4.90, down 1.01% with a trading volume of 168,700 shares and a transaction value of 82.85 million [1] - Jianghe Pharmaceutical (002788) closed at 8.40, down 1.18% with a trading volume of 40,400 shares and a transaction value of 34.10 million [1] - Liuyou Group (603368) closed at 17.96, down 1.32% with a trading volume of 61,800 shares and a transaction value of 111 million [1] - Zhongyao Holdings (000950) closed at 5.16, down 1.34% with a trading volume of 162,400 shares and a transaction value of 84.32 million [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 295 million from main funds, while speculative funds had a net inflow of 132 million and retail investors had a net inflow of 164 million [3]

Group 1 - The company has received a total compensation amount of 56,089,816.67 yuan for the expropriation of three properties located at Sichuan Middle Road, which were previously managed and rented out by the company [2][3] - The expropriation was conducted by the Shanghai Huangpu District Government, with the properties being assessed by a certified real estate appraisal firm [1] - The company held board meetings and a shareholders' meeting to approve the compensation agreement prior to receiving the funds [2] Group 2 - The expropriated properties were primarily used for rental operations, but the expropriation is not expected to have a significant impact on the company's overall business [3] - The compensation amount will be accounted for in the current financial period, potentially leading to a positive effect on the company's annual operating performance, subject to audit confirmation [3]